RT Journal Article
SR Electronic
T1 Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e004434
DO 10.1136/jitc-2021-004434
VO 10
IS 7
A1 Ann W Silk
A1 Christopher A Barker
A1 Shailender Bhatia
A1 Kathryn B Bollin
A1 Sunandana Chandra
A1 Zeynep Eroglu
A1 Brian R Gastman
A1 Kari L Kendra
A1 Harriet Kluger
A1 Evan J Lipson
A1 Kathleen Madden
A1 David M Miller
A1 Paul Nghiem
A1 Anna C Pavlick
A1 Igor Puzanov
A1 Guilherme Rabinowits
A1 Emily S Ruiz
A1 Vernon K Sondak
A1 Edward A Tavss
A1 Michael T Tetzlaff
A1 Isaac Brownell
YR 2022
UL http://jitc.bmj.com/content/10/7/e004434.abstract
AB Nonmelanoma skin cancers (NMSCs) are some of the most commonly diagnosed malignancies. In general, early-stage NMSCs have favorable outcomes; however, a small subset of patients develop resistant, advanced, or metastatic disease, or aggressive subtypes that are more challenging to treat successfully. Recently, immune checkpoint inhibitors (ICIs) have been approved by the US Food and Drug Administration (FDA) for the treatment of Merkel cell carcinoma (MCC), cutaneous squamous cell carcinoma (CSCC), and basal cell carcinoma (BCC). Although ICIs have demonstrated activity against NMSCs, the routine clinical use of these agents may be more challenging due to a number of factors including the lack of predictive biomarkers, the need to consider special patient populations, the management of toxicity, and the assessment of atypical responses. With the goal of improving patient care by providing expert guidance to the oncology community, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). The expert panel drew on the published literature as well as their own clinical experience to develop recommendations for healthcare professionals on important aspects of immunotherapeutic treatment for NMSCs, including staging, biomarker testing, patient selection, therapy selection, post-treatment response evaluation and surveillance, and patient quality of life (QOL) considerations, among others. The evidence- and consensus-based recommendations in this CPG are intended to provide guidance to cancer care professionals treating patients with NMSCs.